{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:09:45Z","timestamp":1790744985664,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis Vaccines and Diagnostics Pty Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.vaccine.2014.05.069","type":"journal-article","created":{"date-parts":[[2014,7,3]],"date-time":"2014-07-03T16:16:37Z","timestamp":1404404197000},"page":"4791-4798","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children"],"prefix":"10.1016","volume":"32","author":[{"given":"Bing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Haji Ali Afzali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7570","key":"10.1016\/j.vaccine.2014.05.069_bib0005","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/bmj.38968.683958.AE","article-title":"Meningococcal disease and its management in children","volume":"333","author":"Hart","year":"2006","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.vaccine.2014.05.069_bib0010","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/clinids\/14.2.515","article-title":"Meningococcal meningitis in sub-Saharan Africa: a model for the epidemic process","volume":"14","author":"Moore","year":"1992","journal-title":"Clin Infect Dis"},{"issue":"18","key":"10.1016\/j.vaccine.2014.05.069_bib0015","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Meningococcal disease","volume":"344","author":"Rosenstein","year":"2001","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.vaccine.2014.05.069_bib0020","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1056\/NEJM199710023371404","article-title":"Bacterial meningitis in the United States in 1995","volume":"337","author":"Schuchat","year":"1997","journal-title":"N Engl J Med"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2014.05.069_bib0025","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1086\/648963","article-title":"Epidemiological profile of meningococcal disease in the United States","volume":"50","author":"Harrison","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2014.05.069_bib0030","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.05.069_bib0035","series-title":"The Australian immunisation handbook","year":"2013"},{"issue":"3","key":"10.1016\/j.vaccine.2014.05.069_bib0040","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1542\/peds.2008-0581","article-title":"Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study","volume":"123","author":"Borg","year":"2009","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.vaccine.2014.05.069_bib0045","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/hv.7.4.14434","article-title":"Cost impact of complications in meningococcal disease: evidence from a United States managed care population","volume":"7","author":"Davis","year":"2011","journal-title":"Hum Vaccines"},{"issue":"5","key":"10.1016\/j.vaccine.2014.05.069_bib0050","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1086\/520303","article-title":"Complications and sequelae of meningococcal disease in Quebec, Canada, 1990\u20131994","volume":"26","author":"Erickson","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2014.05.069_bib0055","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/j.ehrm.2011.08.001","article-title":"Costs of sequelae associated with invasive meningococcal disease: findings from a US managed care population","volume":"2","author":"Karve","year":"2011","journal-title":"Health Outcomes Res Med"},{"issue":"9","key":"10.1016\/j.vaccine.2014.05.069_bib0060","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case\u2013control study","volume":"11","author":"Viner","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2014.05.069_bib0070","series-title":"Epidemiology and prevention of vaccine-preventable diseases","author":"Atkinson","year":"2000"},{"key":"10.1016\/j.vaccine.2014.05.069_bib0075","series-title":"Notification rate of meningococcal disease (invasive), Australia, 2012 by age group and sex [database on the Internet]","year":"2013"},{"issue":"6","key":"10.1016\/j.vaccine.2014.05.069_bib0080","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1542\/peds.106.6.1500","article-title":"Meningococcal disease prevention and control strategies for practice-based physicians (Addendum: recommendations for college students). Committee on Infectious Diseases","volume":"106","year":"2000","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2014.05.069_bib0085","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/1471-2334-12-202","article-title":"Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000 to 2010","volume":"12","author":"Dang","year":"2012","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2014.05.069_bib0090","first-page":"407","article-title":"Annual report of the Australian Meningococcal Surveillance Programme 2001","volume":"26","year":"2002","journal-title":"Commun Dis Intell Q Rep"},{"issue":"3","key":"10.1016\/j.vaccine.2014.05.069_bib0095","first-page":"E251","article-title":"Annual report of the Australian Meningococcal Surveillance Programme, 2011","volume":"36","author":"Lahra","year":"2012","journal-title":"Commun Dis Intell Q Rep"},{"key":"10.1016\/j.vaccine.2014.05.069_bib0100","series-title":"Joint Committee on Vaccination and Immunisation (JCVI) interim position statement on use of Bexsero\u00ae meningococcal B vaccine in the UK","year":"2013"},{"issue":"3","key":"10.1016\/j.vaccine.2014.05.069_bib0105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/11587330-000000000-00000","article-title":"Hospital costs, length of stay and mortality associated with childhood, adolescent and young adult meningococcal disease in the US","volume":"9","author":"Davis","year":"2011","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"10.1016\/j.vaccine.2014.05.069_bib0110","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4161\/hv.7.1.13692","article-title":"Cost of acute hospitalization and post-discharge follow-up care for meningococcal disease in the United States","volume":"7","author":"Davis","year":"2011","journal-title":"Hum Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2014.05.069_bib0115","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1524-4733.2006.00113.x","article-title":"Managing meningococcal disease in the United States: hospital case characteristics and costs by age","volume":"9","author":"O\u2019Brien","year":"2006","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2014.05.069_bib0120","series-title":"The epidemiology of meningococcal disease in Victoria, 1997","author":"Robinson","year":"2002"},{"issue":"1","key":"10.1016\/j.vaccine.2014.05.069_bib0125","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40272-012-0006-0","article-title":"Counting the cost of meningococcal disease: scenarios of severe meningitis and septicemia","volume":"15","author":"Wright","year":"2013","journal-title":"Paediatr Drugs"},{"issue":"3","key":"10.1016\/j.vaccine.2014.05.069_bib0130","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/1358863X08091738","article-title":"Why cost-of-illness studies are important and inform policy","volume":"13","author":"Durand-Zaleski","year":"2008","journal-title":"Vasc Med"},{"issue":"1","key":"10.1016\/j.vaccine.2014.05.069_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/524041","article-title":"Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States","volume":"46","author":"Ortega-Sanchez","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2014.05.069_bib0140","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0749-3797(02)00462-2","article-title":"Vaccinating first-year college students living in dormitories for meningococcal disease: an economic analysis","volume":"23","author":"Scott","year":"2002","journal-title":"Am J Prev Med"},{"issue":"5","key":"10.1016\/j.vaccine.2014.05.069_bib0145","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1542\/peds.2004-2514","article-title":"Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States","volume":"115","author":"Shepard","year":"2005","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.vaccine.2014.05.069_bib0150","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1046\/j.1440-1754.2001.00652.x","article-title":"Meningococcal vaccination for adolescents? An economic evaluation in Victoria","volume":"37","author":"Skull","year":"2001","journal-title":"J Paediatr Child Health"},{"issue":"7341","key":"10.1016\/j.vaccine.2014.05.069_bib0155","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/bmj.324.7341.809","article-title":"Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales","volume":"324","author":"Trotter","year":"2002","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.vaccine.2014.05.069_bib0160","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/0272989X05284109","article-title":"Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model","volume":"26","author":"Trotter","year":"2006","journal-title":"Med Decis Mak"},{"issue":"23","key":"10.1016\/j.vaccine.2014.05.069_bib0165","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact","volume":"31","author":"Christensen","year":"2013","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2014.05.069_bib0170","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2165\/00019053-200523040-00004","article-title":"Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis","volume":"23","author":"Miller","year":"2005","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.vaccine.2014.05.069_bib0175","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/INF.0000000000000043","article-title":"The clinical burden and predictors of sequelae following invasive meningococcal disease in Australian children","volume":"33","author":"Wang","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2014.05.069_bib0180","series-title":"6401.0 consumer price index, Australia. TABLE 11. CPI: group, sub-group and expenditure class, index numbers by capital city","year":"2012"},{"key":"10.1016\/j.vaccine.2014.05.069_bib0185","series-title":"Bootstrap methods and their application","author":"Davison","year":"1997"},{"issue":"1","key":"10.1016\/j.vaccine.2014.05.069_bib0190","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/INF.0b013e3182706b89","article-title":"The disease burden of invasive meningococcal serogroup B disease in Canada","volume":"32","author":"Bettinger","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2014.05.069_bib0195","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1258\/1355819042250249","article-title":"Multiple regression of cost data: use of generalised linear models","volume":"9","author":"Barber","year":"2004","journal-title":"J Health Serv Res Policy"},{"issue":"7 Suppl. 1","key":"10.1016\/j.vaccine.2014.05.069_bib0200","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1097\/MLR.0b013e31819c94a1","article-title":"Issues for the next generation of health care cost analyses","volume":"47","author":"Basu","year":"2009","journal-title":"Med Care"},{"key":"10.1016\/j.vaccine.2014.05.069_bib0205","series-title":"Hospital performance: cost per casemix-adjusted separation","year":"2013"},{"issue":"5","key":"10.1016\/j.vaccine.2014.05.069_bib0210","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/sim.1647","article-title":"Committee for Proprietary Medicinal Products (CPMP): points to consider on adjustment for baseline covariates","volume":"23","year":"2004","journal-title":"Statist Med"},{"issue":"11","key":"10.1016\/j.vaccine.2014.05.069_bib0215","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1097\/INF.0b013e3182615297","article-title":"Costs of meningitis sequelae in children in Dakar, Senegal","volume":"31","author":"Griffiths","year":"2012","journal-title":"Pediatr Infect Dis J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14007555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14007555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T23:20:33Z","timestamp":1538436033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14007555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":42,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0264410X14007555"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.05.069","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.05.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}